
An observational cohort study investigated the effects of low adherence to weekly cisplatin in patients with head and neck cancer undergoing definitive chemoradiation. Analysis of 119 patients revealed that 42.9% had low adherence, defined as receiving fewer than 5 cycles totaling 200 mg/m2. Results showed significantly worse overall survival, progression-free survival, and distant failure outcomes in these patients. Poor performance status was linked to lower adherence. Findings highlight the need for strategies to improve adherence and patient outcomes.
Like
Save
Share